AURA3: Osimertinib in Patients with T790M-Positive Advanced NSCLC - 100459

Spotlight
Video

AURA3: Osimertinib in Patients with T790M-Positive Advanced NSCLC

moasc has 207 videos Subscribe Here

Loading........
Description: Daniela Bota, MD of UC Irvine Health gives an overview of the AURA3 trial and the use of osimertinib in patients with advanced non-small cell lung cancer at the 2017 MOASC Spotlight on Clinical Oncology in Huntington Beach, CA.

Abstract 9005: CNS Response to Osimertinib in Patients (pts) with T790M-Positive Advanced NSCLC: Data from a Randomized Phase III Trial (AURA3)
Shared By : moasc
Posted on : 08/03/17
Added : 6 months ago



Recommended

Nothing found.

More From moasc

Nothing found.